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Background & Aims: The	 prevalence	 of	 non‐alcoholic	 fatty	 liver	 disease	 (NAFLD)	
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1  | INTRODUC TION
Non‐alcoholic	fatty	liver	disease	(NAFLD)	is	characterized	by	hepatic	
steatosis	 in	 the	absence	of	excessive	alcohol	use,	 and	 is	emerging	
as	 the	most	 common	 cause	 of	 chronic	 liver	 disease	 as	 a	 result	 of	
the	global	obesity	epidemic.	The	spectrum	of	NAFLD	ranges	from	




NAFLD	 coincides	 with	 plasma	 lipoprotein	 abnormalities,	 in‐
cluding	 elevations	 in	 apolipoprotein	 (Apo)B‐containing	 lipopro‐
teins,	an	 increase	 in	the	ratio	of	ApoB	to	ApoA‐I,	decreased	 levels	
of	 high‐density	 lipoprotein	 (HDL)	 cholesterol	 and	 increased	 levels	
of	 low‐density	 lipoprotein	 (LDL)	 cholesterol.3‐5	 Enhanced	 delivery	
of	adipose	tissue‐derived	fatty	acids	to	the	liver	provides	a	central	













Consequently,	 prevention	 and	 treatment	 of	 dyslipidaemia	 are	 es‐





atotoxicity.14,15	 Nevertheless,	 statin	 treatment	 appears	 to	 be	 safe	
in	NAFLD	patients	with	elevated	liver	enzymes.16‐19	In	addition,	ex‐
perimental	animal	models	with	chronic	liver	injury	have	shown	that	



















2  | MATERIAL S AND METHODS
2.1 | Study population
The	 study	 is	 a	 cross‐sectional	 analysis	 of	 the	 population‐based	
Lifelines	 Cohort	 Study	 including	 a	 total	 of	 167	 729	 persons	 from	
the	northern	part	of	the	Netherlands.28,29	All	participants	provided	
written	 informed	 consent.	 The	 medical	 ethics	 committee	 of	 the	
University	of	Groningen,	the	Netherlands,	approved	the	study	con‐
forming	to	the	Declaration	of	Helsinki.28,29
Only	 subjects	 with	 data	 required	 to	 calculate	 Fatty	 Liver	
Index	 (FLI),30	 used	 as	 a	 proxy	 of	 NAFLD	 (described	 below),	 and	
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cardiovascular	risk	scores	were	included.	Exclusion	criteria	were	par‐
ticipants	<18	years,	non‐fasting	participants	at	time	of	blood	collec‐
tion,	 immigrants,	 participants	with	 self‐reported	 excessive	 alcohol	
use	(>1	drink	in	women	and	>2	drinks	in	men	per	day),	those	previ‐
ous	diagnosed	with	hepatitis	or	cirrhosis	as	well	as	all	participants	
using	 lipid‐lowering	drugs.	The	use	of	 lipid‐lowering	drugs	 (statins,	
fibrates,	bile	acid	sequestrates,	nicotinic	acid	and	derivatives,	com‐










Venous	 blood	 samples	 were	 processed	 for	 laboratory	 mea‐
surements	 with	 standardized	 laboratory	 measurements	 and	 quality	
assessment	control	at	the	Department	of	Laboratory	Medicine	of	the	
University	Medical	Center	Groningen,	the	Netherlands.28,29	High	sen‐
sitivity	 C‐reactive	 protein	 (CRP),	 alanine	 aminotransferase	 (ALT),	 as‐
partate	 aminotransferase	 (AST),	 gamma‐glutamyltransferase	 (GGT),	
alkaline	 phosphatase	 (ALP),	 albumin	 (measured	 with	 a	 BCG	 albumin	
assay	kit	for	colorimetric	testing	on	a	Roche	Modular	P	chemistry	an‐




In	 order	 to	 categorize	 subjects	 with	 a	 high	 probability	 for	
the	 diagnosis	 of	 NAFLD,	 the	 FLI	 was	 used.	 FLI	 was	 calculated	
according	 to	 the	 formula	 published	 by	 Bedogni	 et	 al.30	 FLI	 =	 







biomarkers	are	 the	preferred	diagnostic	 tool	with	 the	FLI	currently	
F I G U R E  1  Flow	chart	of	the	study	population




the	 NAFLD	 fibrosis	 score	 (NFS),	 the	 formula	 published	 by	 Angulo	
et	al	was	used.32	NFS	=	−1.675	+	0.037	×	age	(years)	+	0.094	×	BMI	
(kg/m2)	 +	 1.13	 ×	 impaired	 fasting	 glucose/presence	 of	 diabetes	










sitivity	 of	 74%,	 specificity	 of	 71%	 and	 positive	 predictive	 value	 of	
43%	and	a	high	cut‐off	of	≥2.67	was	used	to	diagnose	the	presence	
TA B L E  1  Clinical	and	biochemical	characteristics	in	27	173	subjects	with	a	Fatty	Liver	Index	(FLI)	<	60	and	in	7067	subjects	with	a	
FLI	≥	60
 
FLI < 60 
N = 27 173 (79.4%)
FLI ≥ 60 
N = 7067 (20.6%) P‐value
Baseline	characteristics
Sex:	men/women,	n (%) 8783	(32.3)/18	390	(67.7) 3927	(55.6)/3140	(44.4) <0.001
Age	(y),	mean	±	SD 42.5	±	12.0 46.4	±	10.9 <0.001
BMI	(kg/m2),	median (IQR) 24.5	(22.7‐26.5) 30.6	(28.5‐33.7) <0.001
BMI
Normal;	≤25	kg/m2,	n	(%) 15	718	(57.8) 116	(1.6) <0.001
Overweight;	25‐30	kg/m2,	n	(%) 10	399	(38.3) 2701	(38.2) 0.939
Obese;	≥30	kg/m2,	n	(%) 1056	(3.9) 4250	(60.1) <0.001
Waist	circumference	(cm)    
Men,	median	(IQR) 91	(86‐95) 105	(100‐110) <0.001
Women,	median	(IQR) 84	(77‐90) 105	(100‐111) <0.001
Smoking,	n	(%) 4952	(18.4) 1449	(20.7) <0.001
Blood	tests
CRP	(mg/L),	median	(IQR) 1.0	(0.5‐2.2) 2.2	(1.1‐5.0) <0.001
ALT	(U/L),	median	(IQR) 18	(13‐24) 28	(20‐40) <0.001
AST	(U/L),	median	(IQR) 22	(19‐26) 25	(21‐30) <0.001
GGT	(U/L),	median	(IQR) 18	(14‐25) 33	(24‐48) <0.001
ALP	(U/L),	mean	±	SD 60	±	17 71	±	21 <0.001
Albumin	(g/L),	mean	±	SD 45.0	±	0.2 44.7	±	0.2 <0.001
HbA1c	(mmol/mol),	mean	±	SD 36.9	±	4.0 39.2	±	6.0 <0.001
HbA1c	(%),	mean	±	SD 5.5	±	0.4 5.7	±	0.5 <0.001
Fasting	glucose	(mmol/L),	median	(IQR) 4.8	(4.5‐5.1) 5.2	(4.9‐5.6) <0.001
Total	cholesterol	(mmol/L),	mean	±	SD 5.0	±	0.9 5.5	±	1.0 <0.001
HDL	cholesterol	(mmol/L),	mean	±	SD 1.5	±	0.4 1.2	±	0.3 <0.001
LDL	cholesterol	(mmol/L),	mean	±	SD 3.1	±	0.9 3.6	±	0.9 <0.001
Non‐HDL	cholesterol	(mmol/L),	median	(IQR) 3.4	(2.8‐4.1) 4.3	(3.6‐4.9) <0.001
Triglycerides	(mmol/L),	median	(IQR) 0.9	(0.7‐1.1) 1.6	(1.2‐2.2) <0.001
ApoB	(g/L),	mean	±	SD 0.9	±	0.1 1.0	±	0.2 <0.001
ApoA‐I	(g/L),	mean	±	SD 1.5	±	0.3 1.3	±	0.2 <0.001
Comorbidities
Type	2	diabetes	mellitus,	n	(%) 233	(0.9) 407	(5.8) <0.001
Metabolic	syndrome,	n	(%) 1296	(4.8) 3504	(49.7) <0.001
Abdominal	obesity,	n	(%) 6600	(24.3) 5741	(81.2) <0.001
Hyperglycaemia,	n	(%) 1822	(6.7) 1911	(27.1) <0.001
Hypertension,	n	(%) 8111	(29.9) 4222	(59.8) <0.001
(Continues)
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FLI < 60 
N = 27 173 (79.4%)
FLI ≥ 60 
N = 7067 (20.6%) P‐value
Elevated	TG,	n	(%) 1620	(6.0) 3085	(43.7) <0.001
Low	HDL	cholesterol,	n	(%) 4235	(15.6) 3181	(45.0) <0.001
Cardiovascular	disease,	n	(%) 2044	(7.5) 616	(8.7) 0.001
Impaired	renal	function,	n	(%)) 2248	(8.3) 1341	(19.0) <0.001














TA B L E  2   (Continued)
TA B L E  2  Cardiovascular	risk	according	to	ESC/EAS	dyslipidaemia	guideline	in	27	173	subjects	with	a	Fatty	Liver	Index	(FLI)	<	60	and	in	
7067	subjects	with	a	FLI	≥	60
 
FLI < 60 
N = 27 173 (79.4%)
FLI ≥ 60 
N = 7067 (20.6%) P‐value
Estimated	10‐y	predicted	CVD	risk
Low	risk,	n	(%) 19	882	(73.2) 3587	(50.8) < 0.001
Medium	risk,	n	(%) 2683	(9.9) 1195	(16.9) < 0.001
High	risk,	n	(%) 2313	(8.5) 1305	(18.5) < 0.001
Very	high	risk,	n	(%) 2295	(8.4) 980	(13.9) < 0.001
Need	for	drug	intervention	strategy	as	function	of	CVD	risk	and	LDL	cholesterol	level
No	intervention,	n	(%) 19	743	(72.7) 3482	(49.3) < 0.001
Lifestyle	intervention	(if	uncontrolled	drug	consideration),	n	(%) 3198	(11.8) 1395	(19.7) < 0.001
Drug	intervention	(statin)	with	concomitant	lifestyle	intervention,	n	(%) 4232	(15.6) 2190	(31.0) < 0.001
Primary	treatment	LDL	cholesterol	target
High	LDL	cholesterol	(≥1.8	mmol/L)	in	very	high‐risk	subjects,	n	(%) 2199	(8.1) 966	(13.7) < 0.001
High	LDL	cholesterol	(≥2.6	mmol/L)	in	high‐risk	subjects,	n	(%) 2033	(7.5) 1224	(17.3) < 0.001
High	LDL	cholesterol	(≥3.0	mmol/L)	in	low‐	to	moderate‐risk	subjects,	n	(%) 11	555	(42.5) 3557	(50.3) < 0.001
Secondary	treatment	non‐HDL	cholesterol	target
High	non‐HDL	cholesterol	(≥2.6	mmol/L)	in	very	high‐risk	subjects,	n	(%) 1867	(6.9) 952	(13.5) < 0.001
High	non‐HDL	cholesterol	(≥3.4	mmol/L)	in	high‐risk	subjects,	n	(%) 1582	(5.8) 1160	(16.4) < 0.001
High	non‐HDL	cholesterol	(≥3.8	mmol/L)	in	moderate‐risk	subjects,	n	(%) 1680	(6.2) 948	(13.4) < 0.001
Secondary	treatment	ApoB	target
High	ApoB	lipoprotein	(≥80	mg/dL)	in	very	high‐risk	subjects,	n	(%) 119	(0.5) 57	(0.9) < 0.001




















narrowing	 of	 the	 carotid	 arteries	 or	 history	 of	 angioplasty,	 bypass	
surgery,	 transient	 ischaemic	accident	or	stroke.13	Estimated	10‐year	
cardiovascular	 risk	 (based	on	age,	 sex,	 systolic	blood	pressure,	 total	
cholesterol	level	and	smoking),	estimated	10‐year	cardiovascular	risk	
groups	(based	on	10‐year	cardiovascular	risk,	presence	of	CVD,	T2D,	
chronic	 kidney	 disease	 and	 markedly	 elevated	 total	 cholesterol	 or	
blood	pressure)	and	indication	for	statin	treatment	(based	on	estimated	
10‐year	 cardiovascular	 risk	 groups	 and	 LDL	 cholesterol	 level)	 were	
also	defined	according	to	the	ESC/EAS	Guideline	for	the	Management	
of	Dyslipidaemias.13	Impaired	renal	function	was	defined	as	estimated	
glomerular	 filtration	 rate	 (eGFR)	 <60	 mL/min/1.73	 m2,	 calculated	
using	the	Modification	of	Diet	in	Renal	Disease	Study	Equation.
2.3 | Statistical analysis
Statistical	 analyses	 were	 performed	 with	 SPSS	 software	 (version	
25.0,	 IBM	 Corporation,	 Armonk,	 NY).	 Data	 are	 expressed	 using	
means	 with	 standard	 deviations	 (SD),	 medians	 with	 interquar‐
tile	 ranges	 (IQR)	 and	 in	 numbers	 with	 percentages.	 Normality	 of	
distribution	 was	 assessed	 and	 checked	 for	 skewness	 using	 the	
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(Figure	1).	Our	study	group	was	predominantly	female	(62.9%)	with	
a	mean	age	of	43	years.
Suspected	 NAFLD,	 defined	 as	 FLI	 ≥	 60,	 was	 present	 in	 7067	
(20.6%)	subjects.	Table	1	shows	the	clinical	and	laboratory	charac‐







Estimated	 10‐year	 predicted	 cardiovascular	 risk	 was	 higher	 in	
subjects	with	 a	 FLI	 ≥	 60	 compared	with	 subjects	with	 a	 FLI	 <	 60	
(Table	2);	very	high	cardiovascular	risk	(13.9%	vs	8.4%),	high	cardio‐
vascular	risk	(18.5%	vs	8.5%),	medium	cardiovascular	risk	(16.9%	vs	
9.9%)	 and	 low	cardiovascular	 risk	 (50.8%	vs	73.2%),	 all	P < 0.001. 
Consequently,	 subjects	with	a	FLI	≥	60	had	an	approximately	 two	





In	 subjects	with	 suspected	NAFLD	and	a	NFS	>	0.676	vs	 sub‐
jects	with	suspected	NAFLD	and	a	NFS	≤	0.676,	essentially	similar	
differences	 in	 CVD	 risk	 and	 LDL	 cholesterol	 treatment	 interven‐
tion	 strategies	were	 found	 (Table	 4).	 Estimated	 10‐year	 predicted	
total	 very	 high	 cardiovascular	 risk	 was	 approximately	 four	 times	








Multivariable	 logistic	 regression	 analyses	 were	 subsequently	
performed	in	order	to	establish	the	extent	to	which	statin	therapy	
was	independently	associated	with	a	FLI	≥	60	(Table	6,	Figure	2A).	
After	 adjustment	 for	 age,	 sex,	 current	 smoking,	presence	of	MetS	
and	 impaired	 renal	 function,	 indication	 for	 statin	 treatment	 was	
TA B L E  4  Cardiovascular	risk	according	to	ESC/EAS	dyslipidaemia	guideline	in	6969	subjects	with	suspected	NAFLD	and	a	NAFLD	
fibrosis	score	(NFS)	≤	0.676	and	in	71	subjects	with	suspected	NAFLD	and	a	NFS	>	0.676
 
NFS ≤ 0.676 
N = 6969 (99.0%)
NFS > 0.676 
N = 71 (1.0%) P‐value
Estimated	10‐y	predicted	CVD	risk
Low	risk,	n	(%) 3562	(51.1) 10	(14.1) <0.001
Medium	risk,	n	(%) 1182	(17.0) 7	(9.9) 0.112
High	risk,	n	(%) 1291	(18.5) 9	(12.7) 0.206
Very	high	risk,	n	(%) 934	(13.4) 45	(63.4) <0.001
Need	for	drug	intervention	strategy	as	function	of	CVD	risk	and	LDL	cholesterol	level
No	intervention,	n	(%) 3455	(49.6) 12	(16.9) <0.001
Lifestyle	intervention	(if	uncontrolled	drug	consideration),	n	(%) 1382	(19.8) 7	(9.9) 0.036
Drug	intervention	(statin)	with	concomitant	lifestyle	intervention,	n	(%) 2132	(30.6) 52	(73.2) <0.001
Primary	treatment	LDL	cholesterol	target
High	LDL	cholesterol	(≥1.8	mmol/L)	in	very	high‐risk	subjects,	n	(%) 920	(13.2) 45	(63.4) <0.001
High	LDL	cholesterol	(≥2.6	mmol/L)	in	high‐risk	subjects,	n	(%) 1212	(17.4) 7	(9.9) 0.095
High	LDL	cholesterol	(≥3.0	mmol/L)	in	low‐	to	moderate‐risk	subjects,	n	(%) 3531	(50.7) 11	(15.5) <0.001
Secondary	treatment	non‐HDL	cholesterol	target
High	non‐HDL	cholesterol	(≥2.6	mmol/L)	in	very	high‐risk	subjects,	n	(%) 908	(13.0) 43	(60.6) <0.001
High	non‐HDL	cholesterol	(≥3.4	mmol/L)	in	high‐risk	subjects,	n	(%) 1148	(16.5) 7	(9.9) 0.134
High	non‐HDL	cholesterol	(≥3.8	mmol/L)	in	moderate‐risk	subjects,	n	(%) 938	(13.5) 4	(5.6) 0.054
Secondary	treatment	ApoB	target
High	ApoB	lipoprotein	(≥80	mg/dL)	in	very	high‐risk	subjects,	n	(%) 57	(0.9) 0	(0) 1.000
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positively	associated	with	a	FLI	≥	60	(Table	6,	Model	1,	OR	1.38,	95%	
CI:	1.23‐1.53).	This	positive	association	was	also	demonstrated	after	
additional	 adjustment	 for	 individual	 MetS	 components	 (Table	 6,	









Model	 2,	 AUC	 =	 0.823	 (95%	 CI:	 0.816‐0.830,	 P	 <	 0.001);	 Model	
3,	 AUC	 =	 0.856	 (95%	 CI:	 0.845‐0.867,	 P	 <	 0.001)	 and	 Model	 4,	
AUC	=	0.869	(95%	CI:	0.858‐0.879,	P	<	0.001).
4  | DISCUSSION
In	 this	 cross‐sectional	 analysis	 in	 a	 large	 population‐based	 cohort	
study,	we	demonstrated	 that	 statin‐naive	 subjects	with	 suspected	
NAFLD,	 and	 suspected	 advanced	 fibrosis,	 have	 a	 significantly	 in‐












tion	 of	 cardiovascular	 diseases	 by	 decreasing	 the	 synthesis	 of	
cholesterol	 in	 the	 liver	by	 inhibition	of	 the	mevalonate	pathway	
through	 a	 competitive	 inhibitory	 effect	 on	 3‐hydroxy‐3‐methyl‐
glutaryl	CoA	 reductase,	which	 results	 in	 lowering	of	 LDL,	VLDL	
and	 consequently	 in	 lower	 triglycerides.38	 Also,	 statins	 have	 an	
effect	on	inhibition	of	inflammatory	pathways,	reduction	of	endo‐




























































































































































































































































































































































































































































































































































































































































































































































































































































that	 statin	 therapy	may	even	have	beneficial	effects	 in	NAFLD.	 In	
human	studies,	the	administration	of	statins	resulted	in	an	improve‐
ment	 of	 ultrasonographic	 amount	 of	 hepatic	 steatosis.40	 Studies	
with	 biopsy‐proven	 NAFLD	 and	 NASH	 showed	 mainly	 positive	

























Model 1 Model 2 Model 3 Model 4
OR (95% CI) P‐value OR (95% CI) P‐value OR (95% CI) P‐value OR (95% CI) P‐value
Age 1.03	(1.03‐1.04) <0.001 1.03	(1.03‐1.03) <0.001 1.04	(1.04‐1.05) <0.001 1.04	(1.03‐1.05) <0.001
Sex	(male	vs	
female)
1.06	(0.97‐1.15) 0.189 1.16	(1.06‐1.27) 0.001 0.99	(0.85‐1.15) 0.993 1.01	(0.85‐1.19) 0.951
FLI	≥	60	vs	<	60 1.38	(1.23‐1.53) <0.001 1.26	(1.13‐1.41) <0.001     
NFS	>	0.676	vs	≤	
0.676
    5.89	(3.26‐10.63) <0.001 5.03	(2.76‐9.17) <0.001
Current	smoking	
(yes/no)
1.37	(1.25‐1.49) <0.001 1.39	(1.27‐1.52) <0.001 1.43	(1.20‐1.69) <0.001 1.46	(1.23‐1.74) <0.001
MetS	(yes/no) 1.72	(1.55‐1.91) <0.001   1.69	(1.46‐1.95) <0.001   
Abdominal	obe‐
sity	(yes/no)
  1.04	(0.95‐1.15) 0.358   1.22	(0.98‐1.54) 0.080
Hyperglycaemia	
(yes/no)
  2.46	(2.22‐2.71) <0.001   2.52	(2.17‐2.93) <0.001
Hypertension	
(yes/no)
  1.22	(1.12‐1.32) <0.001   1.17	(1.01‐1.37) 0.038
Elevated	triglyc‐
erides	(yes/no)
  1.23	(1.10‐1.37) <0.001   1.20	(1.03‐1.40) 0.019
Low	HDL	choles‐
terol	(yes/no)





























for	 hepatotoxicity.	 In	 a	 correspondence	 letter,	 Taii	 et	 al	 described	
in	9960	patients	with	NAFLD	and	high	LDL	cholesterol	that	71%	of	
patients	 received	 statin	 therapy,	 but	 additional	 cardiovascular	 or	
metabolic	 information	 from	 these	 subjects	was	 unfortunately	 not	
presented.26












to	 be	 addressed.	 First,	 its	 cross‐sectional	 design	 does	 not	 allow	
cause‐effect	relationships	to	be	established	with	certainty.	Second,	
immigrants	were	 excluded	 in	 order	 to	 select	 a	Western	 European	
population.	While	 this	 likely	 limits	extrapolation	of	our	 findings	 to	







sented	 results.	 Fourth,	 the	 proportion	 of	 subjects	with	 suspected	
fibrosis	 in	 our	 study	 is	 quite	 low	 amounting	 to	 only	 1%.	 This	 low	





diovascular	 risk	 depends	 on	 systolic	 blood	 pressure,	 irrespective	
of	antihypertensive	drugs.	Therefore,	use	of	short‐term	antihyper‐
tensive	drugs	could	have	underestimated	the	risk	of	cardiovascular	
disease	and	classification	 into	a	 lower	cardiovascular	 risk	category	
could	have	occurred.	Finally,	 the	FLI	 and	NFS	are	not	 an	absolute	
measure	of	hepatic	 fat	accumulation	and	 level	of	 fibrosis	and	thus	





consuming,	 expensive	 and	 also	 not	 feasible	 in	 large	 observational	
















brosis	could	benefit	 from	 lipid‐lowering	 treatment	and	statin	 ther‐
apy	should	thus	be	encouraged.
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